Epoetin alfa biosimilar - Sedico

Drug Profile

Epoetin alfa biosimilar - Sedico

Alternative Names: Epoetin 2000 I.U. Sedico; Epoetin 4000 I.U. Sedico

Latest Information Update: 28 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sedico
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia; Chemotherapy-induced anaemia

Most Recent Events

  • 28 Feb 2014 Launched prior to 2014 for Chemotherapy-induced anaemia in Egypt (IV)
  • 28 Feb 2014 Launched prior to 2014 for Chemotherapy-induced anaemia in Egypt (SC)
  • 28 Feb 2014 Launched prior to 2014 for Anaemia in Egypt (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top